Journal
AMERICAN JOURNAL OF CLINICAL DERMATOLOGY
Volume 14, Issue 4, Pages 261-272Publisher
ADIS INT LTD
DOI: 10.1007/s40257-013-0013-0
Keywords
-
Categories
Ask authors/readers for more resources
Melanoma is an immunogenic tumor that can induce a natural immune response. A number of immunotherapy-based approaches have been developed over the past decades, and certain degrees of effectiveness were achieved by the use of cytokines, adoptive cell transfer and T-cell immune modulators. Currently, interleukin-2 and the immune stimulatory antibody, ipilimumab, are the only two approved immunotherapies for metastatic melanoma, but various new therapies are in promising developmental stages. This comprehensive review will discuss the latest achievements of immunotherapy and emerging directions for the management of advanced melanoma.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available